BMO Capital upgraded Chemours to Outperform from Market Perform with a price target of $34, up from $19. The analyst says the “accounting issue” is now behind the company. While Chemours’ Q1 guidance was well below expectations and communication around 2024 was limited, “we are at/near the inflection point in a number of CC‘s businesses,” the analyst tells investors in a research note. The firm says that as the company gets past a host of “one-offs”, its earnings should improve through 2024 and into 2024 which is not appreciated in this “show me” story. Time with Chemours’ CEO “confirmed she has a solid plan to drive the company going forward,” adds BMO.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CC:
- The Chemours Company Class Action: Levi & Korsinsky LLP Reminds The Chemours Company Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of May 20, 2024 – CC
- Chemours price target lowered to $30 from $32 at Barclays
- Chemours price target raised to $28 from $21 at UBS
- Chemours falls -9.1%
- Chemours Company Q4 and Full Year 2023 Financial Webcast Summary